PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a specific type of colorectal cancer where you have two or more tumors at the same time (called multiple primary colorectal cancer).
- Lab tests show that at least one of your tumors has a high level of a genetic marker called MSI or a deficiency in the proteins that repair DNA (dMMR).
- Your cancer is locally advanced (stage T3 or T4, with or without lymph node involvement) but has not spread to other organs (no distant metastases).
- You have not had any prior treatment for this cancer, such as surgery, chemotherapy, radiation, immunotherapy, or hormone therapy.
- You do not have serious heart, lung, liver, kidney, bone marrow, or autoimmune problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new approach for people with locally advanced low rectal cancer that is pMMR type. You would receive a combination of an immunotherapy drug (anti-PD-1) with chemotherapy (FOLFOXIRI) and radiation before any surgery, to try to shrink the tumor as much as possible.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
This trial tests giving PD-1 immunotherapy with chemotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes for patients who haven't had prior cancer treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.